Pmv Pharmaceuticals
Highly Engaged Employees
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Research Way, Princeton, New Jersey, 0...Phone Number
(609) 642-6670Website
www.pmvpharma.comRevenue
$9.9 MillionStock Symbol
PMVPIndustry
About Pmv Pharmaceuticals
Pmv Pharmaceuticals Org Chart
Is Pmv Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Pmv Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Pmv Pharmaceuticals has new funding data
Check out if Pmv Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Pmv Pharmaceuticals launches new products
Check if Pmv Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Pmv Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Pmv Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Pmv Pharmaceuticals
Recommended Actions
Find VP level buyers at Pmv Pharmaceuticals
Find more new buyers
Compare Similar Companies to Pmv Pharmaceuticals
Compare insights from companies similar to Pmv Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pmv Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pmv Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pmv Pharmaceuticals.
Pmv Pharmaceuticals financials insights
Gather financial insights about Pmv Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$30M
Series B
$74M
Series C
$62M
Series D
$70M
Stock Offering
$212M
Pmv Pharmaceuticals Tech Stack
A closer look at the technologies used by Pmv Pharmaceuticals
Most Recent Scoops
Pmv Pharmaceuticals News & Media
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock,PMV Pharma Announces Proposed Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of itsPMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational Phase 2 trial is assessing rezatapopt as monotherapy at a dose of 2000 mg once-daily in patients withPMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pmv Pharmaceuticals
PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company incorporated in 2013 and headquartered in Princeton, New Jersey. The company is focused on the research and development of small molecule therapies that target mutant p53, one of the most commonly altered tumor suppressor genes in human cancer. PMV's approach centers on struct... Read More
